Supplemental Figure 3 from Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Year: 2023
Type: supplementary-materials
Abstract: S3. Cisplatin and anti-PD-L1 blockade induced a slight but short-lived delay of tumor growth in MOC2 tumor-bearing mice that did not improve survival. Mice were injected with 1 x 105 MOC2 tumor cells in the right flank. After 14 days, mice with palpable tumors were randomized and treated concurrently with cisplatin (5 mg/kg/week) and/or anti-PD-L1 antibody (200 mcg twice/week x 3 doses). Black line: control; Blue line: CDDP only; Gray line: anti-PD-L1; Green line: combination. A, Tumor volume over time. Data are mean {plus minus} SEM, n = 8 mice per group. *p<0.05 vs. control by linear regression curve comparison. B, Kaplan-Meier survival plot.
Authors: Linda Tran, Clint T. Allen, Roy Xiao, Ellen Moore, Ruth Davis, So-Jin Park, Katie Spielbauer, Carter Van Waes, Nicole C. Schmitt
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362628746